Developer docs
API playgroundTry for free, no card

Search company profiles

Alimera Sciences

Full company profile

uuid0005ktx

Namestring
Alimera Sciences
Legal namestring
Alimera Sciences
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Alimera Sciences is a biopharmaceutical company that develops and commercializes sustained-release intravitreal implants for retinal disease. The company's product portfolio consists of two FDA-approved corticosteroid implants: YUTIQ (fluocinolone acetonide intravitreal implant, 0.18 mg), approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and ILUVIEN (fluocinolone acetonide intravitreal implant, 0.19 mg), approved for diabetic macular edema. Both products share the same proprietary platform architecture, delivering sustained release of fluocinolone acetonide over approximately 36 months from a single intravitreal injection, eliminating the need for repeated intraocular injections and addressing the compliance and treatment-burden challenges associated with chronic retinal inflammation.

Alimera serves a narrow specialist customer base — ophthalmologists and retina specialists who treat chronic inflammatory and diabetic retinal conditions — and reaches patients through specialty pharmacy distribution and direct relationships with ophthalmology clinics across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The company monetizes primarily through prescription product sales to healthcare providers and payers at undisclosed specialty pharmaceutical pricing, supplemented by royalty streams associated with its intravitreal implant franchise. YUTIQ generated USD 28.3 million in 2022, a 67% increase over 2021, indicating accelerating commercial uptake heading into the acquisition.

In September 2024, Alimera Sciences was acquired by ANI Pharmaceuticals (NASDAQ: ANIP), becoming a wholly-owned subsidiary integrated into ANI's retina-focused rare disease business. Post-acquisition, ANI further consolidated the franchise's economics by acquiring a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million in March 2025. The company had previously been publicly listed on NASDAQ under the ticker ALIM prior to delisting following the ANI transaction.

Short descriptiontext

Alimera Sciences is a biopharmaceutical company that develops and commercializes FDA-approved sustained-release intravitreal implants (YUTIQ and ILUVIEN) for chronic non-infectious uveitis and diabetic macular edema, serving ophthalmologists and retina specialists across the US and Europe. Acquired by ANI Pharmaceuticals in September 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAlpharetta, United States
HQ citystring
Alpharetta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal disease therapeutics, intravitreal implants, ophthalmic pharmaceuticals, uveitis treatments, diabetic macular edema
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Ophthalmic Goods Manufacturing339115
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Pharmaceuticals
Revenue model3 records
1Product Sales - YUTIQ
TypeOne Time License
Description

Sales of FDA-approved YUTIQ intravitreal implant for chronic non-infectious uveitis. YUTIQ generated USD 28.3 million in 2022 (67% increase from 2021).

globenewswire.com
2Product Sales - ILUVIEN
TypeOne Time License
Description

Sales of ILUVIEN intravitreal implant for diabetic macular edema. ILUVIEN generates ongoing royalties as part of ANI Pharmaceuticals' retina-focused business following the September 2024 acquisition.

globenewswire.com
3Royalty Revenue
TypeLicensing Royalties
Description

In March 2025, ANI Pharmaceuticals acquired a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million, indicating ongoing royalty streams from these products.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1YUTIQ
Description

FDA-approved intravitreal implant for chronic non-infectious uveitis

globenewswire.com
+1 more record
Core offering1 text field

Alimera Sciences develops, manufactures, and commercializes FDA-approved intravitreal implants for retinal disease. Its two commercial products — YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg) for chronic non-infectious uveitis affecting the posterior segment, and ILUVIEN (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema — deliver sustained corticosteroid release for approximately 36 months, reducing the need for repeated intravitreal injections. Following its September 2024 acquisition by ANI Pharmaceuticals, the products are sold to ophthalmology and retina specialists through specialty pharmacy and direct specialty distribution channels.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Alimera Sciences was a pharmaceutical company specializing in ophthalmic therapeutics, focused on the development and commercialization of prescription ophthalmic pharmaceuticals. Following its acquisition by ANI Pharmaceuticals in September 2024, Alimera's portfolio consists primarily of two sustained-release intravitreal implants: YUTIQ (for chronic non-infectious uveitis) and ILUVIEN (for diabetic macular edema). Both products deliver fluocinolone acetonide via proprietary intravitreal implant technology providing sustained drug release over extended periods. The portfolio addresses retinal disease conditions and is commercialized primarily in the United States with international market presence.

Product and service2 records
1YUTIQ
CategoryOphthalmic Pharmaceuticals
Description

YUTIQ is an FDA-approved intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The implant provides sustained release of fluocinolone acetonide over approximately 36 months, reducing the need for repeated intravitreal injections and addressing long-term treatment burden for patients with chronic posterior uveitis.

2ILUVIEN
CategoryOphthalmic Pharmaceuticals
Description

ILUVIEN is an intravitreal corticosteroid implant indicated for the treatment of diabetic macular edema (DME). It provides sustained delivery of fluocinolone acetonide over an extended period, offering an alternative to frequent intravitreal injections for patients with diabetic eye disease requiring long-acting anti-inflammatory therapy.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ANI Pharmaceuticals acquired Alimera Sciences in September 2024, strengthening its retina-focused business portfolio. The acquisition included Alimera's products YUTIQ and ILUVIEN, both FDA-approved intravitreal implants for ophthalmic conditions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

EyePoint Pharmaceuticals develops sustained-release ocular drug delivery implants including DURYSTA (bimatoprost intracameral implant) and is a direct competitor in long-duration ophthalmic implants. Both companies target sustained drug delivery in the eye with biodegradable implant technology addressing chronic retinal and glaucoma conditions.

TypeBroad incumbent
Description

Regeneron commercializes Eylea (aflibercept), the dominant anti-VEGF therapy for diabetic macular edema and other retinal diseases. Eylea is the leading first-line DME treatment that competes directly against ILUVIEN for the same patient population, positioning Regeneron as a broad incumbent in the retinal therapeutics market.

TypeBroad incumbent
Description

Roche/Genentech markets Lucentis (ranibizumab) and Susvimo, both used in diabetic macular edema and other retinal conditions. As a broad incumbent in ophthalmology biologics, Roche represents the established anti-VEGF paradigm against which ILUVIEN's steroid implant positioning must compete.

TypeBroad incumbent
Description

Novartis commercializes Beovu (brolucizumab) for DME and related retinal conditions and has a broad ophthalmology portfolio. Novartis competes with Alimera's franchise for retinal specialists' prescribing share in DME and represents a broad incumbent with deep commercial reach.

TypeBroad incumbent
Description

Bausch + Lomb is a diversified ophthalmology company with products spanning retinal disease, glaucoma, dry eye, and surgical devices. Its retinal franchise (including the recently divested Bausch + Lomb Stellaris Elite and anti-VEGF partnerships) competes broadly with Alimera's specialty pharma focus.

TypeEmerging player
Description

Clearside Biomedical develops suprachoroidal drug delivery technology for retinal diseases, including XIPERE (triamcinolone acetonide suprachoroidal injectable) for uveitic macular edema. Clearside is an emerging competitor targeting the same uveitis patient population as YUTIQ via a different delivery route.

TypeEmerging player
Description

Adverum is developing ADVM-022 (ixoberogene soroparvovec), a gene therapy targeting diabetic macular edema and wet AMD via single intravitreal injection. As an emerging player with a long-acting treatment paradigm for DME, Adverum represents a future competitive threat to ILUVIEN.

TypeEmerging player
Description

Kodiak Sciences develops KSI-301 (tarcocimab tedromer), an antibody biopolymer conjugate for retinal vascular diseases including DME. Kodiak is an emerging player pursuing longer-dosing-interval anti-VEGF therapy that could pressure conventional treatment paradigms in DME.

TypeEmerging player
Description

Outlook Therapeutics is developing ONS-5010 / LYTENAVA, an ophthalmic formulation of bevacizumab for wet AMD and other retinal conditions. As an emerging biosimilar-style player targeting retinal disease, Outlook represents potential future competition in the broader DME treatment landscape.

TypeBroad incumbent
Description

IVERIC bio (now part of Astellas following 2023 acquisition) developed Izervay for geographic atrophy and other retinal therapeutics. As a retinal-focused player now integrated into a global pharma, it represents a comparable trajectory of ophthalmic specialty biotech being absorbed by a larger strategic buyer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alimera Sciences

Ophthalmic Pharmaceuticalsalimerasciences.com

Alimera Sciences is a biopharmaceutical company that develops and commercializes FDA-approved sustained-release intravitreal implants (YUTIQ and ILUVIEN) for chronic non-infectious uveitis and diabetic macular edema, serving ophthalmologists and retina specialists across the US and Europe. Acquired by ANI Pharmaceuticals in September 2024.

What Alimera Sciences does

Alimera Sciences is a biopharmaceutical company that develops and commercializes sustained-release intravitreal implants for retinal disease. The company's product portfolio consists of two FDA-approved corticosteroid implants: YUTIQ (fluocinolone acetonide intravitreal implant, 0.18 mg), approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and ILUVIEN (fluocinolone acetonide intravitreal implant, 0.19 mg), approved for diabetic macular edema. Both products share the same proprietary platform architecture, delivering sustained release of fluocinolone acetonide over approximately 36 months from a single intravitreal injection, eliminating the need for repeated intraocular injections and addressing the compliance and treatment-burden challenges associated with chronic retinal inflammation.

Alimera serves a narrow specialist customer base — ophthalmologists and retina specialists who treat chronic inflammatory and diabetic retinal conditions — and reaches patients through specialty pharmacy distribution and direct relationships with ophthalmology clinics across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The company monetizes primarily through prescription product sales to healthcare providers and payers at undisclosed specialty pharmaceutical pricing, supplemented by royalty streams associated with its intravitreal implant franchise. YUTIQ generated USD 28.3 million in 2022, a 67% increase over 2021, indicating accelerating commercial uptake heading into the acquisition.

In September 2024, Alimera Sciences was acquired by ANI Pharmaceuticals (NASDAQ: ANIP), becoming a wholly-owned subsidiary integrated into ANI's retina-focused rare disease business. Post-acquisition, ANI further consolidated the franchise's economics by acquiring a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million in March 2025. The company had previously been publicly listed on NASDAQ under the ticker ALIM prior to delisting following the ANI transaction.

Alimera Sciences firmographics

Firmographics
Name
Alimera Sciences
Legal name
Alimera Sciences
Website
https://alimerasciences.com
Company type
Private
Founded year
2003
Operating status
Acquired
Headcount range
251–500 employees
Short description
Alimera Sciences is a biopharmaceutical company that develops and commercializes FDA-approved sustained-release intravitreal implants (YUTIQ and ILUVIEN) for chronic non-infectious uveitis and diabetic macular edema, serving ophthalmologists and retina specialists across the US and Europe. Acquired by ANI Pharmaceuticals in September 2024.
Ownership category
akta.pro rank

Alimera Sciences industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Ophthalmic Goods Manufacturing (339115)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Retinal disease therapeutics
  • Intravitreal implants
  • Ophthalmic pharmaceuticals
  • Uveitis treatments
  • Diabetic macular edema

Where Alimera Sciences is headquartered

Location

Headquarters

HQ city
Alpharetta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alimera Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - YUTIQ: Sales of FDA-approved YUTIQ intravitreal implant for chronic non-infectious uveitis. YUTIQ generated USD 28.3 million in 2022 (67% increase from 2021).
  2. Product Sales - ILUVIEN: Sales of ILUVIEN intravitreal implant for diabetic macular edema. ILUVIEN generates ongoing royalties as part of ANI Pharmaceuticals' retina-focused business following the September 2024 acquisition.
  3. Royalty Revenue: In March 2025, ANI Pharmaceuticals acquired a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million, indicating ongoing royalty streams from these products.

Distribution channels2 records

Marketing channels3 records

Alimera Sciences product offering

Product offering

Core offering

Alimera Sciences develops, manufactures, and commercializes FDA-approved intravitreal implants for retinal disease. Its two commercial products — YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg) for chronic non-infectious uveitis affecting the posterior segment, and ILUVIEN (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema — deliver sustained corticosteroid release for approximately 36 months, reducing the need for repeated intravitreal injections. Following its September 2024 acquisition by ANI Pharmaceuticals, the products are sold to ophthalmology and retina specialists through specialty pharmacy and direct specialty distribution channels.

Product overview

Alimera Sciences was a pharmaceutical company specializing in ophthalmic therapeutics, focused on the development and commercialization of prescription ophthalmic pharmaceuticals. Following its acquisition by ANI Pharmaceuticals in September 2024, Alimera's portfolio consists primarily of two sustained-release intravitreal implants: YUTIQ (for chronic non-infectious uveitis) and ILUVIEN (for diabetic macular edema). Both products deliver fluocinolone acetonide via proprietary intravitreal implant technology providing sustained drug release over extended periods. The portfolio addresses retinal disease conditions and is commercialized primarily in the United States with international market presence.

Differentiator

Problem solved

Functional benefit

Brands

  • YUTIQ: FDA-approved intravitreal implant for chronic non-infectious uveitis
  • ILUVIEN

Products and services

  • YUTIQ YUTIQ is an FDA-approved intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The implant provides sustained release of fluocinolone acetonide over approximately 36 months, reducing the need for repeated intravitreal injections and addressing long-term treatment burden for patients with chronic posterior uveitis.
  • ILUVIEN ILUVIEN is an intravitreal corticosteroid implant indicated for the treatment of diabetic macular edema (DME). It provides sustained delivery of fluocinolone acetonide over an extended period, offering an alternative to frequent intravitreal injections for patients with diabetic eye disease requiring long-acting anti-inflammatory therapy.

Companies that use Alimera Sciences

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Alimera Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Alimera Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ANI PharmaceuticalscoreStrategic or Co-development PartnerANI Pharmaceuticals acquired Alimera Sciences in September 2024, strengthening its retina-focused business portfolio. The acquisition included Alimera's products YUTIQ and ILUVIEN, both FDA-approved intravitreal implants for ophthalmic conditions.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Alimera Sciences competitors and assessment

Company assessment

Direct peers

  • EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular drug delivery implants including DURYSTA (bimatoprost intracameral implant) and is a direct competitor in long-duration ophthalmic implants. Both companies target sustained drug delivery in the eye with biodegradable implant technology addressing chronic retinal and glaucoma conditions.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron commercializes Eylea (aflibercept), the dominant anti-VEGF therapy for diabetic macular edema and other retinal diseases. Eylea is the leading first-line DME treatment that competes directly against ILUVIEN for the same patient population, positioning Regeneron as a broad incumbent in the retinal therapeutics market.
  • Roche / Genentech: Roche/Genentech markets Lucentis (ranibizumab) and Susvimo, both used in diabetic macular edema and other retinal conditions. As a broad incumbent in ophthalmology biologics, Roche represents the established anti-VEGF paradigm against which ILUVIEN's steroid implant positioning must compete.
  • Novartis: Novartis commercializes Beovu (brolucizumab) for DME and related retinal conditions and has a broad ophthalmology portfolio. Novartis competes with Alimera's franchise for retinal specialists' prescribing share in DME and represents a broad incumbent with deep commercial reach.
  • Bausch + Lomb: Bausch + Lomb is a diversified ophthalmology company with products spanning retinal disease, glaucoma, dry eye, and surgical devices. Its retinal franchise (including the recently divested Bausch + Lomb Stellaris Elite and anti-VEGF partnerships) competes broadly with Alimera's specialty pharma focus.
  • IVERIC bio (Astellas): IVERIC bio (now part of Astellas following 2023 acquisition) developed Izervay for geographic atrophy and other retinal therapeutics. As a retinal-focused player now integrated into a global pharma, it represents a comparable trajectory of ophthalmic specialty biotech being absorbed by a larger strategic buyer.

Emerging players

  • Clearside Biomedical: Clearside Biomedical develops suprachoroidal drug delivery technology for retinal diseases, including XIPERE (triamcinolone acetonide suprachoroidal injectable) for uveitic macular edema. Clearside is an emerging competitor targeting the same uveitis patient population as YUTIQ via a different delivery route.
  • Adverum Biotechnologies: Adverum is developing ADVM-022 (ixoberogene soroparvovec), a gene therapy targeting diabetic macular edema and wet AMD via single intravitreal injection. As an emerging player with a long-acting treatment paradigm for DME, Adverum represents a future competitive threat to ILUVIEN.
  • Kodiak Sciences: Kodiak Sciences develops KSI-301 (tarcocimab tedromer), an antibody biopolymer conjugate for retinal vascular diseases including DME. Kodiak is an emerging player pursuing longer-dosing-interval anti-VEGF therapy that could pressure conventional treatment paradigms in DME.
  • Outlook Therapeutics: Outlook Therapeutics is developing ONS-5010 / LYTENAVA, an ophthalmic formulation of bevacizumab for wet AMD and other retinal conditions. As an emerging biosimilar-style player targeting retinal disease, Outlook represents potential future competition in the broader DME treatment landscape.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Alimera Sciences social profiles

Digital presence

Alimera Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alimera Sciences leadership team

Management profile

Number of profiles

Profiles11 records

Alimera Sciences funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alimera Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alimera Sciences

What does Alimera Sciences do?

Alimera Sciences develops, manufactures, and commercializes FDA-approved intravitreal implants for retinal disease. Its two commercial products — YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg) for chronic non-infectious uveitis affecting the posterior segment, and ILUVIEN (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema — deliver sustained corticosteroid release for approximately 36 months, reducing the need for repeated intravitreal injections. Following its September 2024 acquisition by ANI Pharmaceuticals, the products are sold to ophthalmology and retina specialists through specialty pharmacy and direct specialty distribution channels.

Is Alimera Sciences a public or private company?

Alimera Sciences is a private company. It is classified as corporate owned and is currently acquired.

When was Alimera Sciences founded?

Alimera Sciences was founded in 2003. It employs 251 to 500 people.

Where is Alimera Sciences based?

Alimera Sciences is headquartered in Alpharetta, United States, in the North America region.

How does Alimera Sciences make money?

Three revenue lines are on record. Product Sales - YUTIQ is the primary driver. The others are product Sales - ILUVIEN and royalty Revenue.

Who are Alimera Sciences's main competitors?

EyePoint Pharmaceuticals is listed as a direct peer. Broad incumbents are Regeneron Pharmaceuticals, Roche / Genentech, Novartis, Bausch + Lomb and IVERIC bio (Astellas). Emerging players are Clearside Biomedical, Adverum Biotechnologies, Kodiak Sciences and Outlook Therapeutics.

Does Alimera Sciences have an API?

No public API is recorded for Alimera Sciences.

What industry is Alimera Sciences in?

Alimera Sciences's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339113 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireYUTIQ Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and JapanResearchAndMarkets.com published a market analysis report on YUTIQ, an FDA-approved intravitreal implant for chronic non-infectious uveitis, covering sales forecasts and market size through 2034 across eight countries. In March 2025, ANI Pharmaceuticals acquired a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million, strengthening its retina-focused business following its acquisition of Alimera Sciences in September 2024. The report highlights strong revenue growth with YUTIQ generating USD 28.3 million in 2022 (67% increase from 2021) and projects significant market opportunity with the global uveitis treatment market valued at approximately USD 0.8 billion in 2022.openPR.comTrends in Growth, Segment Analysis, and Competitive Strategies Influencing the Ocular Implants MarketThe ocular implants market is projected to reach $27.69 billion by 2030, growing at a compound annual growth rate of 11.1%, driven by advances in technology, increasing demand for vision correction procedures, and developments in ophthalmic biomaterials. In June 2024, ANI Pharmaceuticals, Inc. acquired Alimera Sciences, Inc. to strengthen its ophthalmology portfolio with intravitreal implants Iluvien and Yutiq, while in August 2023, HumanOptics Holding AG launched its ARTIFICIALIRIS SELECT premium iris implant product.Business InsiderANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target PriceOren Livnat reiterated a Buy rating on ANI Pharmaceuticals with a $94 price target, citing the acquisition of Alimera Sciences. The deal is expected to be accretive, adding two steroid implants projected to generate $105 million in 2024 sales. ANI's capital restructuring and record Cortrophin Gel starts further support the outlook.GlobeNewswireANI Pharmaceuticals, Inc. Completes Acquisition of Alimera SciencesANI Pharmaceuticals completed its acquisition of Alimera Sciences, paying $5.50 per share and repaying $72.5 million of Alimera debt. The deal adds about $105 million in 2024 pro forma revenue and is expected to drive high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS.Business InsiderANI Pharmaceuticals, Inc. Completes Acquisition of Alimera SciencesANI Pharmaceuticals completed its acquisition of Alimera Sciences, paying $5.50 per share and repaying $72.5 million of Alimera debt. The deal adds about $105 million in 2024 revenue and expands ANI's Rare Disease segment to roughly 45% of pro forma 2024 revenues. ANI expects high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS.AnipharmaceuticalsANI Pharmaceuticals, Inc. Completes Acquisition of Alimera SciencesANI Pharmaceuticals, Inc. completed its acquisition of Alimera Sciences, adding approximately $105 million in 2024 pro forma revenue and expanding its presence into the ophthalmology market with two new commercial assets. The transaction was funded through a new capital structure that includes $316.25 million in convertible senior notes and a new credit facility, which is expected to reduce annual interest expenses by roughly $39 million. ANI anticipates high single-digit to low double-digit accretion in adjusted non-GAAP EPS for 2025 as it integrates Alimera's durable rare disease portfolio.BenzingaDow Jumps 300 Points; Alimera Sciences Shares Spike HigherU.S. stocks traded mixed on Monday, with the Dow Jones index rising more than 300 points while the NASDAQ declined. Alimera Sciences shares surged 76% after announcing a definitive agreement to be acquired by ANI Pharmaceuticals, whereas Effector Therapeutics plummeted 74% upon announcing the termination of employees and wind-down of operations.BenzingaGenerics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - AANI Pharmaceuticals Inc agreed to acquire Alimera Sciences Inc for $5.50 per share in cash plus a contingent value right of up to $0.50 per share, with ANI also repaying $72.5 million of Alimera debt, in a transaction valuing Alimera at approximately $381 million in upfront consideration. The deal, approved by both boards and expected to close late in Q3 2024, will expand ANI's rare disease segment to approximately 45% of pro forma 2024 revenues and add about $105 million in revenues, while extending its geographic footprint to Germany, the UK, Portugal, and Ireland. ANI expects the transaction to deliver $35–38 million in 2025 adjusted EBITDA with cost synergies, high single-digit to low double-digit accretion in non-GAAP EPS in 2025, and substantial accretion thereafter.AnipharmaceuticalsANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera SciencesANI Pharmaceuticals announced a definitive agreement to acquire Alimera Sciences for approximately $381 million in upfront cash consideration, plus contingent value rights, with the transaction expected to close in late Q3 2024. The acquisition adds Alimera's ophthalmology assets ILUVIEN and YUTIQ to ANI's portfolio, aiming to expand its rare disease business and generate significant revenue accretion. ANI intends to finance the deal using cash on hand and debt financing secured from J.P. Morgan and Blackstone Credit & Insurance.YahooANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera SciencesANI Pharmaceuticals announced plans to expand its Rare Disease Business through the acquisition of Alimera Sciences. This strategic acquisition aims to strengthen ANI Pharmaceuticals' position in the rare disease market.